[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587533":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":11,"centralContacts":39,"locations":45,"responsibleParty":83,"collaborators":11,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":11,"eligibilityCriteria":91,"healthyVolunteers":87,"sex":92,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":11,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":11,"overallStatus":48,"whyStopped":11,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","INDUSTRY",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"SHR-A1912 combined with Rituximab + Gemcitabine + Oxaliplatin","EXPERIMENTAL",null,[13,14,15,16],"Drug: SHR-A1912 Injection","Drug: Rituximab Injection","Drug: Gemcitabine Hydrochloride for Injection","Drug: Oxaliplatin Injection",{"label":18,"type":19,"description":11,"interventionNames":20},"Rituximab + Gemcitabine + Oxaliplatin","ACTIVE_COMPARATOR",[14,15,16],[22,27,31,35],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":11},"DRUG","SHR-A1912 Injection","SHR-A1912 injection.",[9],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"Rituximab Injection","Rituximab injection.",[18,9],{"type":23,"name":32,"description":33,"armGroupLabels":34,"otherNames":11},"Gemcitabine Hydrochloride for Injection","Gemcitabine hydrochloride for injection.",[18,9],{"type":23,"name":36,"description":37,"armGroupLabels":38,"otherNames":11},"Oxaliplatin Injection","Oxaliplatin injection.",[18,9],[40],{"name":41,"role":42,"phone":43,"phoneExt":11,"email":44},"Mengbo Zhao","CONTACT","+86-0518-82342973","mengbo.zhao@hengrui.com",[46,67],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Beijing Cancer Hospital","RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":55,"coordinates":56},"Point",[57,58],116.39723,39.9075,{"lat":58,"lon":57},[61,65],{"name":62,"role":42,"phone":63,"phoneExt":11,"email":64},"Yuqin Song","+86-010-88140650","songyuqin622@163.com",{"name":62,"role":66,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"facility":68,"status":48,"city":69,"state":70,"zip":71,"country":52,"countryCode":53,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Sun Yat-sen University Cancer Center","Guangzhou","Guangdong","510060",{"type":55,"coordinates":73},[74,75],113.25,23.11667,{"lat":75,"lon":74},[78,82],{"name":79,"role":42,"phone":80,"phoneExt":11,"email":81},"Zhiming Li","+86-020-87343392","lzmlzmlzm@yahoo.com",{"name":79,"role":66,"phone":11,"phoneExt":11,"email":11},{"type":84,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100587533","phase-3-a-phase-3-clinical-study-of-shr-a1912-combined-with-r-gemox-versus-r-gemox-in-diffuse-large-b-cell-lymphoma-100587533",false,"NCT06929624","A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","A Phase 3, Open-label, Randomized Study of SHR-A1912 Combined With Rituximab + Gemcitabine + Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","Inclusion Criteria:\n\n1. Histologically confirmed diffuse large B-cell lymphoma (DLBCL).\n2. Have received ≥1 line of systemic antitumor therapy.\n3. At least one bi-dimensionally measurable lesion.\n4. Expected survival of at least 3 months.\n5. Age ≥18 years old and under 80 years old.\n6. The patients voluntarily participated in the study, signed informed consent, had good compliance and were willing to cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Central nervous system lymphoma involvement.\n2. Primary mediastinal (thymus) large B-cell lymphoma.\n3. Patients who have only one prior line therapy and are candidates for stem cell transplantation.\n4. A history of immunodeficiency.\n5. A history of severe cardiovascular disease.\n6. A history of other malignancies within 5 years prior to administration of the first dose.","ALL","18 Years","80 Years",{"count":96,"type":97},280,"ESTIMATED","INTERVENTIONAL",[100],"PHASE3","This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.",[103],"Diffuse Large B-cell Lymphoma","2026-06-29",{"date":106,"type":107},"2026-07-01","ACTUAL",{"date":109,"type":107},"2025-04-24",{"date":111,"type":97},"2028-01",{"name":5,"class":6},2]